tiprankstipranks
Advertisement
Advertisement

GB:AVCT Stock Latest News

Avacta advances pre|CISION oncology pipeline and extends cash runway with £10m raise
Company AnnouncementsAvacta advances pre|CISION oncology pipeline and extends cash runway with £10m raise
4d ago
Avacta to Showcase Next Chapter of pre|CISION Platform at 2026 Science Day
PremiumCompany Announcements
Avacta to Showcase Next Chapter of pre|CISION Platform at 2026 Science Day
5d ago
Avacta doses first patient in Phase 1 trial of new tumor-activated cancer drug AVA6103
PremiumCompany Announcements
Avacta doses first patient in Phase 1 trial of new tumor-activated cancer drug AVA6103
13d ago
Avacta Raises £10m in Oversubscribed Share Placing and Director Subscription
PremiumCompany Announcements
Avacta Raises £10m in Oversubscribed Share Placing and Director Subscription
17d ago
Avacta launches £10m equity raise to extend runway and advance oncology pipeline
PremiumCompany Announcements
Avacta launches £10m equity raise to extend runway and advance oncology pipeline
17d ago
Avacta raises £10m to extend runway and advance oncology pipeline
PremiumCompany AnnouncementsAvacta raises £10m to extend runway and advance oncology pipeline
17d ago
Avacta to Present New pre|CISION Cancer Drug Conjugate Data at 2026 AACR
Premium
Company Announcements
Avacta to Present New pre|CISION Cancer Drug Conjugate Data at 2026 AACR
27d ago
Avacta opens Phase 1 trial for sustained-release tumor-targeted exatecan therapy
Premium
Company Announcements
Avacta opens Phase 1 trial for sustained-release tumor-targeted exatecan therapy
28d ago
Avacta data show pre|CISION cancer drug outperforms leading ADC in preclinical analysis
PremiumCompany Announcements
Avacta data show pre|CISION cancer drug outperforms leading ADC in preclinical analysis
2M ago
Avacta to Spotlight Tumor-Targeted Oncology Platform at TD Cowen Conference
PremiumCompany Announcements
Avacta to Spotlight Tumor-Targeted Oncology Platform at TD Cowen Conference
2M ago
Avacta names Francis Wilson Chief Scientific Officer to drive pre|CISION® oncology platform
PremiumCompany Announcements
Avacta names Francis Wilson Chief Scientific Officer to drive pre|CISION® oncology platform
2M ago
Avacta Lifts Dosing Cap and Sets Path to Efficacy Trials for Faridoxorubicin
PremiumCompany Announcements
Avacta Lifts Dosing Cap and Sets Path to Efficacy Trials for Faridoxorubicin
2M ago
Avacta Wins FDA IND Clearance for Second pre|CISION® Cancer Drug AVA6103
PremiumCompany AnnouncementsAvacta Wins FDA IND Clearance for Second pre|CISION® Cancer Drug AVA6103
3M ago
Avacta Advances Tumor-Targeted Oncology Pipeline and Extends Cash Runway Into Q3 2026
Premium
Company Announcements
Avacta Advances Tumor-Targeted Oncology Pipeline and Extends Cash Runway Into Q3 2026
3M ago
Avacta Names Strand Hanson as Nominated Adviser and Updates Share Capital and Governance Disclosures
Premium
Company Announcements
Avacta Names Strand Hanson as Nominated Adviser and Updates Share Capital and Governance Disclosures
3M ago
Avacta Unveils Promising Data for Tumor-Targeted Cancer Therapy FAP-Exd
PremiumCompany Announcements
Avacta Unveils Promising Data for Tumor-Targeted Cancer Therapy FAP-Exd
4M ago
Avacta’s Faridoxorubicin Shows Promising Results in Salivary Gland Cancer Trials
PremiumCompany Announcements
Avacta’s Faridoxorubicin Shows Promising Results in Salivary Gland Cancer Trials
4M ago
Avacta Group Announces Preliminary Data in Salivary Gland Cancer Trial
PremiumCompany Announcements
Avacta Group Announces Preliminary Data in Salivary Gland Cancer Trial
4M ago
Avacta Unveils Innovative Dual Payload Cancer Therapy
PremiumCompany Announcements
Avacta Unveils Innovative Dual Payload Cancer Therapy
6M ago
Avacta to Present Innovative Oncology Platform Data to Investors
PremiumCompany AnnouncementsAvacta to Present Innovative Oncology Platform Data to Investors
6M ago
Avacta Group Raises £16 Million to Advance Oncology Programs
Premium
Company Announcements
Avacta Group Raises £16 Million to Advance Oncology Programs
6M ago
Avacta’s Faridoxorubicin Shows Promising Phase 1a Results in Cancer Treatment
Premium
Company Announcements
Avacta’s Faridoxorubicin Shows Promising Phase 1a Results in Cancer Treatment
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >